Pharmacogenomic analyses of sunitinib in patients with
pancreatic neuroendocrine tumors

J 2019

Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors

FAZIO, Nicola, Jean-Francois MARTINI, Adina E. CROITORU, Michael SCHENKER, Sherry LI et. al.

Basic information

Original name

Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors

Authors

FAZIO, Nicola (380 Italy), Jean-Francois MARTINI (840 United States of America), Adina E. CROITORU (642 Romania), Michael SCHENKER (642 Romania), Sherry LI (840 United States of America), Brad ROSBROOK (840 United States of America), Kathrine FERNANDEZ (840 United States of America), Jiří TOMÁŠEK (203 Czech Republic, belonging to the institution), Espen THIIS-EVENSEN (578 Norway), Matthew KULKE (840 United States of America) and Eric RAYMOND (250 France)

Edition

Future Oncology, London, Future Medicine Ltd. 2019, 1479-6694

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.660

RIV identification code

RIV/00216224:14110/19:00112848

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.2217/fon-2018-0934

UT WoS

000474879700006

Keywords in English

biomarkers; efficacy; pancreatic neuroendocrine tumor; sunitinib; VEGF

Abstract

V originále

Aim: Evaluate associations between clinical outcomes and SNPs in patients with well-differentiated pancreatic neuroendocrine tumors receiving sunitinib. Patients & methods: Kaplan-Meier and Cox proportional hazards models were used to analyze the association between SNPs and survival outcomes using data from a sunitinib Phase IV (genotyped, n = 56) study. Fisher's exact test was used to analyze objective response rate and genotype associations. Results: After multiplicity adjustment, progression-free and overall survivals were not significantly correlated with SNPs; however, a higher objective response rate was significantly associated with IL1B rs16944 G/A versus G/G (46.4 vs 4.5%; p = 0.001). Conclusion: IL1B SNPs may predict treatment response in patients with pancreatic neuroendocrine tumors. VEGF pathway SNPs are potentially associated with survival outcomes.

Citovat

FAZIO, Nicola, Jean-Francois MARTINI, Adina E. CROITORU, Michael SCHENKER, Sherry LI, Brad ROSBROOK, Kathrine FERNANDEZ, Jiří TOMÁŠEK, Espen THIIS-EVENSEN, Matthew KULKE and Eric RAYMOND. Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors. Future Oncology. London: Future Medicine Ltd., 2019, vol. 15, No 17, p. 1997-2007. ISSN 1479-6694. Available from: https://dx.doi.org/10.2217/fon-2018-0934.

@article{1615257,
   author = {Fazio, Nicola and Martini, JeanandFrancois and Croitoru, Adina E. and Schenker, Michael and Li, Sherry and Rosbrook, Brad and Fernandez, Kathrine and Tomášek, Jiří and ThiisandEvensen, Espen and Kulke, Matthew and Raymond, Eric},
   article_location = {London},
   article_number = {17},
   doi = {http://dx.doi.org/10.2217/fon-2018-0934},
   keywords = {biomarkers; efficacy; pancreatic neuroendocrine tumor; sunitinib; VEGF},
   language = {eng},
   issn = {1479-6694},
   journal = {Future Oncology},
   title = {Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors},
   url = {http://dx.doi.org/10.2217/fon-2018-0934},
   volume = {15},
   year = {2019}
}

TY  - JOUR
ID  - 1615257
AU  - Fazio, Nicola - Martini, Jean-Francois - Croitoru, Adina E. - Schenker, Michael - Li, Sherry - Rosbrook, Brad - Fernandez, Kathrine - Tomášek, Jiří - Thiis-Evensen, Espen - Kulke, Matthew - Raymond, Eric
PY  - 2019
TI  - Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors
JF  - Future Oncology
VL  - 15
IS  - 17
SP  - 1997-2007
EP  - 1997-2007
PB  - Future Medicine Ltd.
SN  - 14796694
KW  - biomarkers
KW  - efficacy
KW  - pancreatic neuroendocrine tumor
KW  - sunitinib
KW  - VEGF
UR  - http://dx.doi.org/10.2217/fon-2018-0934
L2  - http://dx.doi.org/10.2217/fon-2018-0934
N2  - Aim: Evaluate associations between clinical outcomes and SNPs in patients with well-differentiated pancreatic neuroendocrine tumors receiving sunitinib. Patients & methods: Kaplan-Meier and Cox proportional hazards models were used to analyze the association between SNPs and survival outcomes using data from a sunitinib Phase IV (genotyped, n = 56) study. Fisher's exact test was used to analyze objective response rate and genotype associations. Results: After multiplicity adjustment, progression-free and overall survivals were not significantly correlated with SNPs; however, a higher objective response rate was significantly associated with IL1B rs16944 G/A versus G/G (46.4 vs 4.5%; p = 0.001). Conclusion: IL1B SNPs may predict treatment response in patients with pancreatic neuroendocrine tumors. VEGF pathway SNPs are potentially associated with survival outcomes.
ER  -

FAZIO, Nicola, Jean-Francois MARTINI, Adina E. CROITORU, Michael SCHENKER, Sherry LI, Brad ROSBROOK, Kathrine FERNANDEZ, Jiří TOMÁŠEK, Espen THIIS-EVENSEN, Matthew KULKE and Eric RAYMOND. Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors. \textit{Future Oncology}. London: Future Medicine Ltd., 2019, vol.~15, No~17, p.~1997-2007. ISSN~1479-6694. Available from: https://dx.doi.org/10.2217/fon-2018-0934.

Detailed Information on Publication Record